FDA Approves First Generic Drug for Control of Clinical Signs of Equine Cushing’s Disease
The U.S. Food and Drug Administration has approved Zygolide (pergolide tablets) for the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) in horses. PPID is also known as Equine Cushing’s Disease, an endocrine condition affecting the pituitary gland of horses.
Finally Here: Emeprev™ Injectable Gives Your Patients Fast Relief from Vomiting
Vomiting in dogs and cats is no fun for anyone, especially when it lands your patients in the clinic stressed and uncomfortable. Enter Emeprev™, the new FDA-approved injectable solution from Dechra that promises the same trusted antiemetic power as the pioneer drug but with perks that make clinic life smoother.
Dechra Expands Veterinary Scholarship Program with New Focus on Critical Care
Dechra Veterinary Products is strengthening its commitment to the next generation of veterinary professionals by expanding its annual scholarship program in partnership with the American Veterinary Medical Foundation (AVMF). For 2025, the program will award over $60,000 in scholarships to veterinary students and technicians across the United States.
FDA Approves Otiserene® for Treatment of Canine Otitis Externa
Dechra announces the recent FDA approval of Otiserene® (marbofloxacin, terbinafine, and dexamethasone otic suspension) to treat otitis externa in dogs. It is the first single-dose, long-acting otitis externa product to leverage the powerful antibiotic marbofloxacin.